Vistagen Therapeutics Inc — Cash Flow (NASDAQ:VTGN) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics

Quarterly Annual

Cash from operating activities 12.07 M-45.26 M-49.72 M25.81 M42.1 M 60.27 M Cash from investing activities 275.4 K-200.4 K-740.3 K61 K13.15 M 251 K Cash from financing activities 114.1 M10.48 M-1.04 M128.4 M3.21 M 33.2 M Free cash flow 11.8 M-45.46 M-50.24 M25.81 M42.1 M 60.11 M

新闻

Vistagen Therapeutics裁员20%以控制成本

Vistagen Therapeutics reduces workforce by 20 percent to manage costs

VistaGen在TD Cowen大会上展示:聚焦信息素平台技术

VistaGen at TD Cowen Conference: Pherine Platform in Focus

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

VistaGen Therapeutics 2026年第三季度财报电话会议：AI驱动的试验分析亮点

Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

Vistagen Therapeutics公司的fasedienol三期临床试验未达终点

Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%

美国股市收低；截至收盘道琼斯工业平均指数下跌0.47%